Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin’s lymphoma: a probabilistic analysis

Overview of attention for article published in BMC Cancer, October 2020

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (65th percentile)
Good Attention Score compared to outputs of the same age and source (79th percentile)

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 5,609 followers.

At at estimated ICER of $418,122 per QALY gained. https://t.co/pPqYKe83RE

RT @AdamR_UBC: Out today! Our paper evaluating the cost-effectiveness of brentuximab vedotin compared to ABVD as therapy for patients with…

RT @AdamR_UBC: Out today! Our paper evaluating the cost-effectiveness of brentuximab vedotin compared to ABVD as therapy for patients with…

RT @AdamR_UBC: Out today! Our paper evaluating the cost-effectiveness of brentuximab vedotin compared to ABVD as therapy for patients with…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.